0.7958
price up icon0.59%   0.0047
after-market Handel nachbörslich: .80 0.0042 +0.53%
loading
Schlusskurs vom Vortag:
$0.7911
Offen:
$0.72
24-Stunden-Volumen:
1.31M
Relative Volume:
0.50
Marktkapitalisierung:
$3.53M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-11.90M
KGV:
-0.00386
EPS:
-206.0125
Netto-Cashflow:
$-12.75M
1W Leistung:
-15.06%
1M Leistung:
-24.92%
6M Leistung:
-51.48%
1J Leistung:
-82.39%
1-Tages-Spanne:
Value
$0.7089
$0.7988
1-Wochen-Bereich:
Value
$0.7089
$0.9999
52-Wochen-Spanne:
Value
$0.1131
$5.16

Allarity Therapeutics Inc Stock (ALLR) Company Profile

Name
Firmenname
Allarity Therapeutics Inc
Name
Telefon
401-426-4664
Name
Adresse
24 SCHOOL ST., 2ND FLOOR, BOSTON
Name
Mitarbeiter
6
Name
Twitter
Name
Nächster Verdiensttermin
Name
Neueste SEC-Einreichungen
Name
ALLR's Discussions on Twitter

Vergleichen Sie ALLR mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ALLR
Allarity Therapeutics Inc
0.7958 3.53M 0 -11.90M -12.75M -206.01
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
474.56 121.88B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
572.78 62.69B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
550.00 33.54B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
232.95 30.15B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
220.54 25.69B 3.81B -644.79M -669.77M -6.24

Allarity Therapeutics Inc Aktie (ALLR) Neueste Nachrichten

pulisher
09:01 AM

ALLR Shareholders are Encouraged to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm - PR Newswire

09:01 AM
pulisher
Apr 04, 2025

Allarity Therapeutics Inc (ALLR) Is A Good Stock To Invest In - stocksregister.com

Apr 04, 2025
pulisher
Apr 03, 2025

Reviewing Allarity Therapeutics (NASDAQ:ALLR) & Bright Minds Biosciences (NASDAQ:DRUG) - Defense World

Apr 03, 2025
pulisher
Apr 02, 2025

ALLR Stockholders Have Opportunity to Lead Allarity Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire

Apr 02, 2025
pulisher
Apr 01, 2025

US Stocks Likely To Open Mixed After Disappointing Q1 Performance: 'April Does Better After A Weak Q1,' Says Expert - Benzinga

Apr 01, 2025
pulisher
Apr 01, 2025

XPeng, Ultralife And 3 Stocks To Watch Heading Into Tuesday - Benzinga

Apr 01, 2025
pulisher
Mar 31, 2025

Allarity Therapeutics, Inc. SEC 10-K Report - TradingView

Mar 31, 2025
pulisher
Mar 31, 2025

Allarity Therapeutics Reports Full Year 2024 Financial Results and Provides a Business Update - GlobeNewswire

Mar 31, 2025
pulisher
Mar 31, 2025

Allarity's Cancer Drug Shows 17-Month Benefit as Cash Runway Extends to 2027 - Stock Titan

Mar 31, 2025
pulisher
Mar 31, 2025

Allarity Therapeutics, Inc. (NASDAQ:ALLR) Short Interest Update - The AM Reporter

Mar 31, 2025
pulisher
Mar 26, 2025

Allarity Therapeutics (NASDAQ:ALLR) Trading 11% Higher – Still a Buy? - Defense World

Mar 26, 2025
pulisher
Mar 25, 2025

Allarity Therapeutics probes potential stock manipulation By Investing.com - Investing.com Australia

Mar 25, 2025
pulisher
Mar 24, 2025

Allarity Therapeutics probes potential stock manipulation - Investing.com

Mar 24, 2025
pulisher
Mar 24, 2025

Allarity Therapeutics Launches Comprehensive Effort to Combat Potential Illegal Naked Short Selling of Its Shares - GlobeNewswire

Mar 24, 2025
pulisher
Mar 24, 2025

12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga

Mar 24, 2025
pulisher
Mar 24, 2025

Allarity Takes Bold Action Against Market Manipulation: Launches High-Tech Trading Investigation - Stock Titan

Mar 24, 2025
pulisher
Mar 20, 2025

Investigation announced for Long-Term Investors in shares - openPR.com

Mar 20, 2025
pulisher
Mar 19, 2025

ALLR Shareholders Are Encouraged To Join Allarity Therapeutics, Inc. Securities Fraud Investigation With The Schall Law Firm - MENAFN.COM

Mar 19, 2025
pulisher
Mar 17, 2025

Allarity Therapeutics Announces Presentation of Phase 2 - GlobeNewswire

Mar 17, 2025
pulisher
Mar 17, 2025

Allarity Therapeutics Presents Positive Phase 2 Data For Stenoparib In Advanced Ovarian Cancer - Nasdaq

Mar 17, 2025
pulisher
Mar 17, 2025

Allarity Therapeutics Announces Presentation of Phase 2 Clinical Data from Ongoing Trial in Advanced Ovarian Cancer Patients at the 2025 Annual Meeting for the Society of Gynecologic Oncology - The Manila Times

Mar 17, 2025
pulisher
Mar 17, 2025

Allarity reports promising ovarian cancer trial results - Investing.com

Mar 17, 2025
pulisher
Mar 17, 2025

Allarity Therapeutics Announces Presentation of Phase 2 Clinical Data from Ongoing Trial in ... - The Bakersfield Californian

Mar 17, 2025
pulisher
Mar 17, 2025

Breakthrough: New Cancer Drug Achieves 10-Month Complete Response in Advanced Ovarian Cancer Patients - StockTitan

Mar 17, 2025
pulisher
Mar 17, 2025

ALLR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Allarity Therapeutics, Inc. and Encourages Shareholders to Contact the Firm! - ACCESS Newswire

Mar 17, 2025
pulisher
Mar 14, 2025

ALLR Investors Have Opportunity to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm - PrimePublishers.com

Mar 14, 2025
pulisher
Mar 13, 2025

Allarity Therapeutics settles SEC investigation By Investing.com - Investing.com Australia

Mar 13, 2025
pulisher
Mar 13, 2025

SEC Says Allarity Leaders Hid FDA Issue Before Record Stock Drop - news.bloombergtax.com

Mar 13, 2025
pulisher
Mar 13, 2025

Allarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange Commission - GlobeNewswire

Mar 13, 2025
pulisher
Mar 13, 2025

Allarity Therapeutics Announces Final Settlement With The U.S. Securities And Exchange Commission - MarketScreener

Mar 13, 2025
pulisher
Mar 13, 2025

Allarity Therapeutics Reaches Final Settlement With SEC Over Past Disclosures -March 13, 2025 at 09:18 am EDT - Marketscreener.com

Mar 13, 2025
pulisher
Mar 13, 2025

Allarity Therapeutics Announces Final Settlement with SEC Over Previous Disclosures Regarding NDA for Dovitinib - Nasdaq

Mar 13, 2025
pulisher
Mar 13, 2025

Allarity Settles SEC Probe: $2.5M Fine Won't Impact Clinical Trials or 2026 Outlook - StockTitan

Mar 13, 2025
pulisher
Mar 12, 2025

SEC Says Ex-Allarity Execs Concealed Doomed FDA Approval - Law360

Mar 12, 2025
pulisher
Mar 10, 2025

ReShape Lifesciences, Allarity, Exact Sciences, CVS, AbbVie: 5 Health Care Stocks That Led Retail Message Grow - Asianet Newsable

Mar 10, 2025
pulisher
Mar 10, 2025

ReShape Lifesciences, Allarity, Exact Sciences, CVS, AbbVie: 5 Health Care Stocks That Led Retail Message Growth Last Week - MSN

Mar 10, 2025
pulisher
Mar 06, 2025

Allarity Therapeutics Announces Phase 2 Trial of Stenoparib - GlobeNewswire

Mar 06, 2025
pulisher
Mar 06, 2025

Allarity Therapeutics Announces Phase 2 Trial of Stenoparib and Temozolomide for Recurrent Small Cell Lung Cancer - Nasdaq

Mar 06, 2025
pulisher
Mar 06, 2025

Allarity Therapeutics Announces Phase 2 Trial of Stenoparib in Combination with Temozolomide for Recurrent Small Cell Lung Cancer Fully Funded by the US Veterans Administration - The Manila Times

Mar 06, 2025
pulisher
Mar 06, 2025

Can This Dual-Action Cancer Drug Overcome Previous PARP Inhibitor Limitations? - StockTitan

Mar 06, 2025
pulisher
Mar 05, 2025

Allarity Therapeutics, Inc. (NASDAQ:ALLR) Short Interest Up 30.0% in February - Defense World

Mar 05, 2025
pulisher
Mar 04, 2025

BDSX Shrinks Loss With Revenue Growth, ALLR Plans $5Mln Share Buyback, What's The Buzz At PTIX? - RTTNews

Mar 04, 2025
pulisher
Mar 04, 2025

Allarity Therapeutics (NASDAQ:ALLR) Board Authorizes Share Buyback Program - Defense World

Mar 04, 2025
pulisher
Mar 03, 2025

Allarity Therapeutics Announces Board Authorization Of $5 Million Share Repurchase Program - TradingView

Mar 03, 2025
pulisher
Mar 03, 2025

Allarity Therapeutics Announces Board Authorization of $5 Million Share Repurchase Program - GlobeNewswire

Mar 03, 2025
pulisher
Mar 03, 2025

Can Allarity's $5M Share Repurchase Signal Hidden Value in Its Cancer Treatment Pipeline? - StockTitan

Mar 03, 2025
pulisher
Mar 03, 2025

Allarity Board Authorizes Share Repurchase Program - Nasdaq

Mar 03, 2025
pulisher
Feb 27, 2025

ALLR STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Allarity Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 26, 2025

Allarity Therapeutics Announces Dismissal of Securities Class Action Lawsuit - GlobeNewswire

Feb 26, 2025
pulisher
Feb 26, 2025

Legal Victory: How Allarity Therapeutics Defeated Its Securities Class Action Without Paying a Dime - StockTitan

Feb 26, 2025

Finanzdaten der Allarity Therapeutics Inc-Aktie (ALLR)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$60.29
price down icon 0.48%
$68.09
price down icon 1.58%
$17.32
price down icon 0.23%
$31.03
price down icon 0.26%
$86.82
price down icon 1.40%
biotechnology ONC
$220.54
price down icon 7.53%
Kapitalisierung:     |  Volumen (24h):